Kymera Therapeutics Inc (KYMR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2017 | 12-2006 | |
| Cash Flows From Operating Activities | |||
| Net Income | -41,246 | N/A | N/A |
| Depreciation Amortization | 825 | N/A | N/A |
| Accounts receivable | 148 | N/A | N/A |
| Accounts payable and accrued liabilities | 904 | N/A | N/A |
| Other Working Capital | 56,687 | N/A | N/A |
| Other Operating Activity | 587 | 0 | 0 |
| Operating Cash Flow | $17,905 | $N/A | $N/A |
| Cash Flows From Investing Activities | |||
| PPE Investments | -532 | N/A | N/A |
| Purchase Of Investment | -15,954 | N/A | N/A |
| Investing Cash Flow | $-16,486 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||
| Debt Repayment | -371 | N/A | N/A |
| Common Stock Issued | 74 | N/A | N/A |
| Other Financing Activity | 35,208 | 0 | 0 |
| Financing Cash Flow | $34,911 | $N/A | $N/A |
| Beginning Cash Position | 41,459 | N/A | N/A |
| End Cash Position | 77,789 | N/A | N/A |
| Net Cash Flow | $36,330 | $N/A | $N/A |
| Free Cash Flow | |||
| Operating Cash Flow | 17,905 | N/A | N/A |
| Capital Expenditure | -532 | N/A | N/A |
| Free Cash Flow | 17,373 | 0 | 0 |